Q-omics provides the consensus-scored ADGRF1 profile across patient tissues and cancer cell-line models. ADGRF1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, ADGRF1 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, ADGRF1 RNA expression shows 11,490 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight THYM, KIRC, and TGCT as cancer lineages where ADGRF1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADGRF1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADGRF1 survival associations across molecular data types. ADGRF1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADGRF1 RNA expression–survival associations across cancer types. High ADGRF1 expression shows unfavorable associations in THYM, DLBC, ESCA, UCEC and KIRP, but favorable associations in BLCA. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THYM as the clearest survival context for ADGRF1 RNA expression.
This table summarizes ADGRF1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ADGRF1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADGRF1 shows lower tumor expression in KIRC, HNSC, KICH and KIRP and higher tumor expression in LUAD and PAAD. The KIRC box plot shows higher ADGRF1 RNA expression in normal versus tumor tissue (log2 FC = −4.430, t-test p < 0.001).
This table shows molecular features associated with ADGRF1 in patient tissues and cancer cell lines. In patient samples, ADGRF1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ADGRF1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LUNG_NSCLC_LUAD.
